Exhibit 10.2


 


15,000 Units 


 


Each Unit consisting of 


 


One Share of Preferred Stock and 


 


A Warrant to Purchase up to 990.1 Shares
of Common Stock 


 


Ekso Bionics Holdings, Inc.


 


PLACEMENT AGENCY AGREEMENT 


 


December 23, 2015


 


Ladenburg Thalmann & Co. Inc.


As Representative of the several


Placement Agents set forth in Schedule C hereto


c/o Ladenburg Thalmann & Co. Inc.


570 Lexington Avenue, 11th Floor


New York, New York 10022


 


Dear Sirs:


 


1. INTRODUCTION. Ekso Bionics Holdings, Inc., a Nevada
corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions
of this Placement Agency Agreement (this “Agreement”) and the Securities Purchase Agreement in the form of Exhibit
A attached hereto (the “Securities Purchase Agreement”) entered into with the purchasers identified therein
(each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of 15,000 units
(the “Units”), each Unit consisting of (i) one share (the “Shares”) of authorized but
unissued Series A Convertible Preferred Stock, par value $0.001 per share (the “Preferred Stock”) of the Company,
which shares of Preferred Stock shall be convertible into shares of common stock, par value $0.001 per share, of the Company (the
“Common Stock”) and (ii) a warrant (the “Warrants”) to purchase up to 990.1 shares
of Common Stock (the “Warrant Shares”). The Units, the Shares, the shares of Common Stock underlying the Preferred
Stock (the “Conversion Shares”), the Warrants and the Warrant Shares are collectively referred to herein as
the “Securities”. The Shares and the Warrants shall be immediately separable and transferable upon issuance.
The terms of (i) the Preferred Stock are set forth in the form of Certificate of Designation (the “Certificate of
Designation”) to be filed with the Secretary of State of the State of Nevada and (ii) the Warrants are set forth
in the form of Warrant attached as Exhibit B hereto. The Company hereby confirms that Ladenburg Thalmann & Co. Inc.
(“Ladenburg”) and Trout Capital LLC (“Trout”, together with Ladenburg, the “Placement
Agents”) have acted as the Placement Agents in accordance with the terms and conditions hereof. Ladenburg is acting as
the representative of the Placement Agents and in such capacity is hereinafter referred to as the “Representative.”


 


2. AGREEMENT TO ACT AS PLACEMENT AGENTS; PLACEMENT OF THE
UNITS. On the basis of the representations, warranties and agreements of the Company herein contained, and subject to the terms
and conditions set forth in this Agreement:


 





(a) The Company hereby authorizes the Placement Agents to act
as its exclusive agents to solicit offers for the purchase of all or part of the Units from the Company in connection with the
proposed offering of the Units (the “Offering”). Until the Closing Date (as defined below) or earlier upon termination
of this Agreement pursuant to Section 8, the Company shall not, without the prior consent of the Representative, solicit
or accept offers to purchase the Units otherwise than through the Placement Agents.





 






     


     


    

 


(b) The Company hereby acknowledges that the Placement Agents
have agreed, as agents of the Company, to use their commercially reasonable efforts to solicit offers to purchase the Units from
the Company on the terms and subject to the conditions set forth in the Prospectus (as defined below). The Placement Agents shall
use commercially reasonable efforts to assist the Company in obtaining performance by each Purchaser whose offer to purchase the
Units has been solicited by the Placement Agents and accepted by the Company, but the Placement Agents shall not, except as otherwise
provided in this Agreement, be obligated to disclose the identity of any potential purchaser or have any liability to the Company
in the event any such purchase is not consummated for any reason. Under no circumstances will the Placement Agents be obligated
to underwrite or purchase any Units for their own account and, in soliciting purchases of the Units, the Placement Agents shall
act solely as the Company’s agent and not as principal.


 


(c) Subject to the provisions of this Section 2, offers
for the purchase of the Units may be solicited by the Placement Agents as agents for the Company at such times and in such amounts
as the Placement Agents deem advisable. The Placement Agents shall communicate to the Company, orally or in writing, each reasonable
offer to purchase the Units received by them as agents of the Company. The Company shall have the sole right to accept offers to
purchase the Units and may reject any such offer, in whole or in part. The Placement Agents shall have the right to reject any
offer to purchase the Units received by them, in whole or in part, only following notice to the Company of such offer and the Company’s
agreement with the Placement Agent regarding such rejection.


 


(d) The Units are being sold to the Purchasers at an offering
price of $1,000 per Unit. The purchases of the Units by the Purchasers shall be evidenced by the execution of Securities Purchase
Agreement by each of the Purchasers and the Company.


 


(e) As compensation for services rendered, on the Closing Date
(as defined below), the Company shall pay to the Placement Agents by wire transfer of immediately available funds to an account
or accounts designated by the Representative, an aggregate amount equal to 6.2% of the gross proceeds received by the Company
(the “Placement Fee”) from the sale of the Units on such Closing Date. The Placement Agents may retain other
brokers or dealers to act as sub-agents on their behalf in connection with the Offering, the fees of which shall be paid out of
the Placement Fee.


 


(f) No Units which the Company has agreed to sell pursuant to
this Agreement and the Securities Purchase Agreement shall be deemed to have been purchased and paid for, or sold by the Company,
until such Units shall have been delivered to the Purchaser thereof against payment by such Purchaser. If the Company shall default
in its obligations to deliver the Units to a Purchaser whose offer it has accepted, the Company shall indemnify and hold the Placement
Agent harmless against any loss, claim, damage or expense arising from or as a result of such default by the Company in accordance
with the procedures set forth in Section 7(c) herein.


 


3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The
Company represents and warrants to the Placement Agents, as of the date hereof, and agrees with the Placement Agents that:


 


(a) The Company has prepared and filed with the Securities and
Exchange Commission (the “Commission”) in accordance with the provisions of the Securities Act of 1933, as amended,
and the rules and regulations of the Commission thereunder (collectively, the “Act”), a registration statement
on Form S-3 (File No. 333-205168), including a base prospectus (the “Base Prospectus”), relating to, among other
things, the Securities. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto,
at each time of effectiveness under the Act for purposes of Section 11 of the Act, as such section applies to the Placement Agents
(the “Effective Time”), including any required information deemed to be part thereof at the time of effectiveness
pursuant to Rule 430B under the Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder (collectively, the “Exchange Act”) is called the “Registration Statement.” Any
preliminary prospectus supplement to the Base Prospectus that described the Securities and the offering thereof and is used prior
to filing of the Prospectus is called, together with the Base Prospectus, a “Preliminary Prospectus.” The term
“Prospectus” shall mean the prospectus supplement relating to the Securities, together with the Base Prospectus, that
is first filed pursuant to Rule 424(b) under the Act after the date and time that this Agreement is executed and delivered to the
parties hereto. If the Company files another registration statement with the Commission to register a portion of the Securities
pursuant to Rule 462(b) under the Act (the “Rule 462 Registration Statement”), then any reference to “Registration
Statement” herein shall be deemed to include the registration statement on Form S-3 (File No. 333-205168) and the Rule 462
Registration Statement, as each such registration statement may be amended pursuant to the Act. For purposes of this Agreement,
“free writing prospectus” has the meaning ascribed to it in Rule 405 under the Act, and “Issuer Free
Writing Prospectus” shall mean each free writing prospectus prepared by or on behalf of the Company or used or referred
to by the Company in connection with the offering of the Securities. “Time of Sale Information” shall mean the
Preliminary Prospectus together with the free writing prospectuses, if any, each identified in Schedule A hereto and the information
included on Schedule B hereto. All references in this Agreement to the Registration Statement, the Rule 462 Registration Statement,
a Preliminary Prospectus, the Prospectus or the Time of Sale Information, or any amendments or supplements to any of the foregoing,
shall be deemed to refer to and include any documents incorporated by reference therein, and shall include any copy thereof filed
with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”).


 




    1 


     


    

 


Any reference in this Agreement to the Registration Statement,
any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein
pursuant to Item 12 of Form S-3 under the Act, as of the date of the Registration Statement, such Preliminary Prospectus or the
Prospectus, as the case may be, and any reference to any amendment or supplement to the Registration Statement, any Preliminary
Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Exchange Act
that, upon filing, are incorporated by reference therein, as required by paragraph (b) of Item 12 of Form S-3. As used herein,
the term “Incorporated Documents” means the documents that at the time of filing are incorporated by reference
in the Registration Statement, any Preliminary Prospectus, the Prospectus or any amendment or supplement thereto.


 


(b) The Company satisfies all of the requirements of the Act
for use of Form S-3 for the offering of the Securities contemplated hereby. The Company was not at the time of initial filing of
the Registration Statement and at the earliest time thereafter that the Company or another offering participant made a bona fide
offer (within the meaning of Rule 164(h)(2) of the Act) of the Common Stock, is not on the date hereof and will not be on the applicable
Delivery Date, an “ineligible issuer” (as defined in Rule 405 under the Act).


 


(c) The Registration Statement conformed, and any amendment
to the Registration Statement filed after the date hereof will conform in all material respects when filed, to the requirements
of the Act. The most recent Preliminary Prospectus conformed, and the Prospectus will conform in all material respects to the requirements
of the Act when filed with the Commission pursuant to Rule 424(b) under the Act.


 


(d) The Registration Statement does not contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading; provided, that no representation or warranty is made as to information contained in or omitted from the Registration
Statement in reliance upon and in conformity with the written information furnished to the Company through the Representatives
by or on behalf of any Placement Agent specifically for inclusion therein, which shall solely include the twelfth and thirteenth
paragraphs concerning stabilization by the Placement Agents under the caption “Plan of Distribution” in any Preliminary
Prospectus or Prospectus (the “Placement Agents’ Information”).


 


(e)The Registration Statement is effective under the Act,
and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use
of any Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the Company’s knowledge, are threatened under the Act. Any required filing of
any Preliminary Prospectus and/or the Prospectus and any supplement thereto pursuant to Rule 424(b) under the Act has been or will
be made in the manner and within the time period required by such Rule 424(b). Any material required to be filed by the Company
pursuant to Rule 433(d) under the Act has been or will be made in the manner and within the time period by such rules.


 


(f) The Incorporated Documents heretofore filed, when they were
filed (or, if any amendment with respect to any such document was filed, when such amendment was filed), conformed in all material
respects with the requirements of the Exchange Act and the rules and regulations thereunder, and any further Incorporated Documents
so filed will, when they are filed, conform in all material respects with the requirements of the Exchange Act and the rules and
regulations thereunder; no such Incorporated Document when it was filed (or, if an amendment with respect to any such document
was filed, when such amendment was filed), contained an untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading; and no such further Incorporated Document, when it is filed, will contain an untrue statement of a material
fact or will omit to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they are made, not misleading.


 




    2 


     


    

 


(g) The Prospectus will not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided that no representation or warranty is made as to
information contained in or omitted from the Prospectus in reliance upon and in conformity with the Placement Agents’ Information.


 


(h) The Time of Sale Information does not, and will not at the
time of sale of the Securities, contain an untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided that no representation or warranty is made as to information contained in or omitted from the Time of Sale Information
in reliance upon and in conformity with the Placement Agents’ Information.


 


(i) Each Issuer Free Writing Prospectus (including, without
limitation, any road show that is a free writing prospectus under Rule 433 under the Act), when considered together with the Time
of Sale Information at the time of sale of the Securities, did not contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading.


 


(j) Each Issuer Free Writing Prospectus conformed or will conform
in all material respects to the requirements of the Act on the date of first use, and, in reliance upon representations from the
Representative, the Company has complied with all prospectus delivery and any filing requirements applicable to such Issuer Free
Writing Prospectus pursuant to the Act. The Company has not made any offer relating to the Securities that would constitute an
Issuer Free Writing Prospectus without the prior written consent of the Representatives. The Company has retained in accordance
with the Act all Issuer Free Writing Prospectuses that were not required to be filed pursuant to the Act. The Company has taken
all actions necessary so that any “road show” (as defined in Rule 433 under the Act) in connection with the offering
of the Securities will not be required to be filed pursuant to the Act.


 


(k) The capitalization of the
Company is and will be as set forth in the Prospectus as of the date set forth therein. All the outstanding shares of Common Stock
and Preferred Stock of the Company have been, and as of the Closing Date, will be, duly authorized and validly issued, fully paid
and nonassessable and free of any preemptive or similar rights; except as set forth in the Time of Sale Information and the Prospectus,
the Company is not a party to or bound by any outstanding options, warrants or similar rights to subscribe for, or contractual
obligations to issue, sell, transfer or acquire, any of its capital stock or any securities convertible into or exchangeable for
any of such capital stock; the Securities to be issued and sold by the Company hereunder have been duly authorized and, when issued
and delivered against full payment therefor in accordance with the terms of this Agreement and the Securities Purchase Agreement,
will be validly issued, fully paid and nonassessable and free of any preemptive or similar rights; the capital stock of the Company
conforms to the description thereof in the Registration Statement, the Time of Sale Information and the Prospectus (or any amendment
or supplement thereto); the Warrant Shares and the Conversion Shares, when issued, paid for
and delivered upon due exercise of the Warrants and the conversion of the Shares, will be duly authorized and validly issued, fully
paid and nonassessable, will be issued in compliance with all applicable securities laws, and will be free of preemptive or similar
rights; the Warrant Shares and the Conversion Shares have been reserved for issuance; and the delivery of certificates for the
Securities being sold by the Company against payment therefor pursuant to the terms of the Securities Purchase Agreement will pass
valid title to the Securities being sold by the Company, free and clear of any claim, encumbrance or defect in title, to the several
Purchasers purchasing such shares in good faith and without notice of any lien, claim or encumbrance. The certificates for the
Securities being sold by the Company are in valid and sufficient form.


 


(l) Each of the Company and its subsidiaries is duly organized
and validly existing as a corporation, limited liability company or other organization in good standing under the laws of the jurisdiction
of its incorporation or organization with full corporate or organizational power and authority to own, lease and operate its properties
and to conduct its business as presently conducted and as described in the Registration Statement, the Time of Sale Information
and the Prospectus (and any amendment or supplement thereto filed prior to the date hereof) and is duly registered and qualified
to conduct its business and is in good standing in each jurisdiction or place where the nature of its properties or the conduct
of its business requires such registration or qualification, except where the failure to so register or qualify would not have
a material adverse effect on the condition (financial or other), business, properties, or the results of operations of the Company
and its subsidiaries taken as a whole (a “Material Adverse Effect”).


 




    3 


     


    

 


(m) The issued shares of capital stock of each of the Company’s
subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company free and
clear of any security interests, liens, encumbrances, equities or claims. The Company does not have any subsidiaries and does not
own a material interest in or control, directly or indirectly, any other corporation, partnership, joint venture, association,
trust or other business organization, except for subsidiaries that are not significant subsidiaries or as set forth in Exhibit
21 to the Company’s registration statement on Form S-1 (File No. 333-195783). As used in this Agreement, subsidiaries shall
mean direct and indirect subsidiaries of the Company.


 


(n) There are no legal or governmental proceedings pending or,
to the knowledge of the Company, threatened, against the Company or its subsidiaries, or to which the Company or its subsidiaries
or any of their properties are subject, that are required to be described in the Registration Statement or the Prospectus (or any
amendment or supplement thereto) but are not described as required. Except as described in the Registration Statement, the Time
of Sale Information and Prospectus, there is no action, suit, inquiry, proceeding or investigation by or before any court or governmental
or other regulatory or administrative agency or commission pending or, to the knowledge of the Company, threatened, against or
involving the Company or its subsidiaries, which might individually or in the aggregate prevent or adversely affect the transactions
contemplated by this Agreement or result in a Material Adverse Effect, nor to the Company’s knowledge, is there any basis
for any such action, suit, inquiry, proceeding or investigation. There are no (i) agreements, contracts, indentures, leases or
other instruments that are required to be described in the Registration Statement, the Time of Sale Information or the Prospectus
(or any amendment or supplement thereto) or (ii) agreements to be filed as an exhibit to the Registration Statement (clauses (i)
and (ii), collectively, the “Material Contracts”) that are not described, filed or incorporated by reference
in the Registration Statement, the Time of Sale Information and the Prospectus as required by the Act. The Material Contracts have
been duly authorized, executed and delivered by the Company or the applicable subsidiary, constitute valid and binding agreements
of the Company or the applicable subsidiary and are enforceable against the Company or the applicable subsidiary in accordance
with the terms thereof, except as enforceability thereof may be limited by (i) the application of bankruptcy, reorganization, insolvency
and other laws affecting creditors’ rights generally and (ii) equitable principles being applied at the discretion of a court
before which any proceeding may be brought. Neither the Company nor the applicable subsidiary has received notice or been made
aware that any other party is in breach of or default to the Company under any of such contracts.


 


(o) Neither the Company nor any of its subsidiaries is (i) in
violation of (A) its articles of incorporation or bylaws, or other organizational documents, (B) any federal, state or foreign
law, ordinance, administrative or governmental rule or regulation applicable to the Company or any of its subsidiaries, the violation
of which in the case of clause (B) only would have a Material Adverse Effect or (C) any decree of any federal, state or foreign
court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries, the violation of which in
the case of clause (C) only, would have a Material Adverse Effect; or (ii) in default in any material respect in the performance
of any obligation, agreement or condition contained in (A) any bond, debenture, note or any other evidence of indebtedness or (B)
any agreement, indenture, lease or other instrument (each of (A) and (B), an “Existing Instrument”) to which
the Company or any of its subsidiaries is a party or by which any of their properties may be bound, which default would have a
Material Adverse Effect; and to the knowledge of the Company there does not exist any state of facts that constitutes an event
of default on the part of the Company or any of its subsidiaries as defined in such documents or that, with notice or lapse of
time or both, would constitute such an event of default.


 


(p) The Company’s execution and delivery of this Agreement
and the Securities Purchase Agreement and the performance by the Company of its obligations hereunder and thereunder have been
duly and validly authorized by the Company and this Agreement and the Securities Purchase Agreement have been duly executed and
delivered by the Company, and constitute valid and legally binding agreements of the Company, enforceable against the Company in
accordance with their respective terms, except to the extent enforceability may be limited by (i) the application of bankruptcy,
reorganization, insolvency and other laws affecting creditors’ rights generally and (ii) equitable principles being applied
at the discretion of a court before which any proceeding may be brought, except as rights to indemnity and contribution hereunder
may be limited by federal or state securities laws.


 




    4 


     


    

 


(q) None of the issuance and sale of the Securities by the Company,
the execution, delivery or performance of this Agreement and the Securities Purchase Agreement by the Company nor the consummation
by the Company of the transactions contemplated hereby (i) requires any consent, approval, authorization or other order of or registration
or filing with, any court, regulatory body, administrative agency or other governmental body, agency or official (except such as
may be required for the registration of the Securities under the Act, the quotation of the Shares for trading on the OTC Bulletin
Board (the “OTCBB”), the registration of the Common Stock under the Exchange Act and the rules and regulations
of the Commission thereunder and compliance with the securities or Blue Sky laws of various jurisdictions, all of which will be,
or have been, effected in accordance with this Agreement), (ii) conflicts with or will conflict with or constitutes or will constitute
a breach of, or a default under, the Company’s articles of incorporation or the Company’s bylaws or any agreement,
indenture, lease or other instrument to which the Company or any of its subsidiaries is a party or by which any of its properties
may be bound, (iii) violates any statute, law, regulation, ruling, filing, judgment, injunction, order or decree applicable to
the Company or any of its subsidiaries or any of their properties, or (iv) results in a breach of, or default under, or results
in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries
pursuant to, or requires the consent of any other party to, any Existing Instrument, except for such conflicts, breaches, defaults,
liens, charges or encumbrances that will not, individually or in the aggregate, result in a Material Adverse Effect.


 


(r) Except as described in the Time of Sale Information and
the Prospectus, and except for options to purchase capital stock issued pursuant to the Company’s Amended and Restated 2014
Equity Incentive Plan, neither the Company nor any of its subsidiaries has outstanding and at the Closing Date will have outstanding
any options to purchase, or any warrants to subscribe for, or any securities or obligations convertible into, or any contracts
or commitments to issue or sell, any shares of Common Stock or Preferred Stock or any such warrants or convertible securities or
obligations. No holder of securities of the Company has rights to the registration of any securities of the Company as a result
of or in connection with the filing of the Registration Statement or the consummation of the transactions contemplated hereby that
have not been satisfied or heretofore waived in writing.


 


(s) OUM & Co., LLP, the certified public accountants who
have certified the financial statements (including the related notes thereto and supporting schedules) filed as part of the Registration
Statement and the Prospectus (or any amendment or supplement thereto), are independent public accountants as required by the Act
and the Exchange Act.


 


(t) Except as disclosed in the Registration Statement, the Time
of Sale Information and the Prospectus (or any amendment or supplement thereto), since the date of the last balance sheet included
in or incorporated by reference into the Prospectus (i) neither the Company nor any of its subsidiaries has incurred any material
liabilities or obligations, indirect, direct or contingent, or entered into any transaction that is not in the ordinary course
of business, (ii) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business
or properties from fire, flood, windstorm, accident or other calamity, whether or not covered by insurance, (iii) neither the Company
nor any of its subsidiaries has paid or declared any dividends or other distributions with respect to its capital stock and the
Company is not in default under the terms of any class of capital stock of the Company or any outstanding debt obligations, (iv)
there has not been any change in the authorized or outstanding capital stock of the Company or any material change in the indebtedness
of the Company (other than in the ordinary course of business) and (v) there has not been any material adverse change, or any development
involving or that may reasonably be expected to result in a Material Adverse Effect, in the condition (financial or otherwise),
business, properties, net worth, result of operations or prospects of the Company.


 


(u) All offers and sales of the Company’s capital stock
and other debt or other securities prior to the date hereof were made in compliance with or were the subject of an available exemption
from the Act and all other applicable state and federal laws or regulations, or any actions under the Act or any state or federal
laws or regulations in respect of any such offers or sales are effectively barred by effective waivers or statutes of limitation.


 


(v) The Common Stock is registered pursuant to Section 12(g)
of the Exchange Act and is quoted on the OTCBB, and the Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or terminating the quotation of the Common Stock on the
OTCBB, nor has the Company received any notification that the Commission or the OTCBB is contemplating terminating such registration
or quotation.


 




    5 


     


    

 


(w) Other than excepted activity pursuant to Regulation M under
the Exchange Act, the Company has not taken and will not take, directly or indirectly, any action that constituted, or any action
designed to, or that might reasonably be expected to cause or result in or constitute, under the Act or otherwise, stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or for any other
purpose.


 


(x) The Company and each of its subsidiaries have filed, or
have applied for an extension of time to file, all tax returns required to be filed (other than certain state or local tax returns,
as to which the failure to file, individually or in the aggregate, would not have a Material Adverse Effect), which filed returns
are complete and correct, and neither the Company nor any subsidiary is in default in the payment of any taxes that were payable
pursuant to said filed returns or any assessments with respect thereto. Except as disclosed in the Time of Sale Information and
the Prospectus, all deficiencies asserted as a result of any federal, state, local or foreign tax audits have been paid or finally
settled and no issue has been raised in any such audit that, by application of the same or similar principles, reasonably could
be expected to result in a proposed deficiency for any other period not so audited. There are no outstanding agreements or waivers
extending the statutory period of limitation applicable to any federal, state, local or foreign tax return for any period. On the
Closing Date, all stock transfer and other taxes that are required to be paid in connection with the sale of the shares to be sold
by the Company will have been fully paid by the Company and all laws imposing such taxes will have been complied with.


 


(y) Except as set forth in the Time of Sale Information and
the Prospectus, there are no transactions with “affiliates” (as defined in Rule 405 under the Act) or any officer,
director or security holder of the Company (whether or not an affiliate) that are required by the Act to be disclosed in the Registration
Statement. Additionally, no relationship, direct or indirect, exists between the Company or any of its subsidiaries on the one
hand, and the directors, officers, stockholders, customers or suppliers of the Company or any subsidiary on the other hand that
is required by the Act to be disclosed in the Registration Statement, the Time of Sale Information and the Prospectus that is not
so disclosed.


 


(z) The Company is not an “investment company” within
the meaning of the Investment Company Act of 1940, as amended.


 


(aa) Each of the Company and its subsidiaries has good and valid
title to all property (real and personal) described in the Time of Sale Information and the Prospectus as being owned by it, free
and clear of all liens, claims, security interests or other encumbrances except (i) such as are described in the Time of Sale Information
and the Prospectus or (ii) such as are not materially burdensome and has not had or would not result in a Material Adverse Effect
to the use of the property or the conduct of the business of the Company. All property (real and personal) held under lease by
the Company and its subsidiaries is held by it under valid, subsisting and enforceable leases with only such exceptions as in the
aggregate are not materially burdensome and do not have or result in a Material Adverse Effect to the use of the property or the
conduct of the business of the Company.


 


(bb) Except as otherwise disclosed in the Time of Sale Information
and the Prospectus, each of the Company and its subsidiaries has all permits, licenses, franchises, approvals, consents and authorizations
of governmental or regulatory authorities (hereinafter “permit” or “permits”) as are necessary to own its
properties and to conduct its business in the manner described in the Time of Sale Information and the Prospectus, subject to such
qualifications as may be set forth in the Time of Sale Information and the Prospectus, except where the failure to have obtained
any such permit has not had and would not have a Material Adverse Effect; except as otherwise disclosed in the Time of Sale Information
and the Prospectus, each of the Company and its subsidiaries has operated and is operating its business in material compliance
with and not in material violation of all of its obligations with respect to each such permit and no event has occurred that allows,
or after notice or lapse of time would allow, revocation or termination of any such permit or result in any other material impairment
of the rights of any such permit, subject in each case to such qualification as may be set forth in the Time of Sale Information
and the Prospectus; and, except as described in the Time of Sale Information and the Prospectus, such permits contain no restrictions
that are materially burdensome to the Company or any of its subsidiaries.


 




    6 


     


    

 


(cc) The consolidated financial statements of the Company, together
with the related schedules and notes thereto, set forth or incorporated by reference in the Time of Sale Information and the Prospectus
present fairly in all material respects (i) the financial condition of the Company and its consolidated subsidiaries as of the
dates indicated and (ii) the consolidated results of operations, stockholders’ equity and changes in cash flows of the Company
and its consolidated subsidiaries for the periods therein specified; and such financial statements and related schedules and notes
thereto have been prepared in conformity with United States generally accepted accounting principles, consistently applied throughout
the periods involved (except as otherwise stated therein and subject, in the case of unaudited financial statements, to the absence
of footnotes and normal year-end adjustments). There are no other financial statements (historical or pro forma) that are required
to be included or incorporated by reference in the Time of Sale Information and the Prospectus; and the Company does not have any
material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not disclosed in the Time
of Sale Information and the Prospectus; and all disclosures contained in the Time of Sale Information and the Prospectus regarding
“non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with
Regulation G of the Exchange Act and Item 10(e) of Regulation S-K under the Act, to the extent applicable, and present fairly in
all material respects the information shown therein and the Company’s basis for using such measures. The interactive data
in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines
applicable thereto.


 


(dd) The Company and its subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain accountability for assets, (iii) access to assets is permitted
only in accordance with management’s general or specific authorizations, (iv) the recorded accountability for assets is compared
with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) the interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents
the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines
applicable thereto.


 


(ee) The Company has established and maintains and evaluates
“disclosure controls and procedures” (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange Act); except
as disclosed in the Registration Statement, the Time of Sale Information and the Prospectus (or any amendment or supplement thereto),
such disclosure controls and procedures are designed to ensure that material information relating to the Company, including its
consolidated subsidiaries, is made known to the Company’s Chief Executive Officer and its Chief Financial Officer by others
within those entities, and such disclosure controls and procedures are effective to perform the functions for which they were established;
the Company’s independent auditors and the Audit Committee of the Board of Directors of the Company have been advised of
(i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which could adversely affect the Company’s ability to record, process, summarize, and report financial data and (ii) any
fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s
internal control over financial reporting; since the date of the most recent evaluation of such disclosure controls and procedures,
except as described in the Registration Statement, the Preliminary Prospectus and the Prospectus, there have been no significant
changes in internal control over financial reporting or in other factors that could significantly affect internal control over
financial reporting, including any corrective actions with regard to significant deficiencies and material weaknesses; the principal
executive officers (or their equivalents) and principal financial officers (or their equivalents) of the Company have made all
certifications required by the Sarbanes-Oxley Act (the “Sarbanes-Oxley Act”) and any related rules and regulations
promulgated by the Commission, and the statements contained in each such certification are complete and correct; the Company and
its subsidiaries are, and the Company has taken all necessary actions to ensure that the Company’s directors and officers
in their capacities as such are, each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley
Act and the rules and regulations of the Commission promulgated thereunder.


 


(ff) The Company and, to the knowledge of the Company, the Company’s
directors or officers, in their capacities as such, are each in compliance in all material respects with Section 402 of the Sarbanes-Oxley
Act and the rules and regulations promulgated thereunder.


 


(gg) The Company has not, prior to the date hereof, made any
offer or sale of securities which could be “integrated” for purposes of the Act with the offer and sale of the Securities
pursuant to the Registration Statement and the Prospectus; and except as disclosed in the Time of Sale Information and the Prospectus,
the Company has not sold or issued any security during the 180-day period preceding the date of the Prospectus, including but not
limited to any sales pursuant to Rule 144A or Regulation D or S under the Act, other than shares of Common Stock issued pursuant
to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options,
rights or warrants as described in the Time of Sale Information and the Prospectus.


 




    7 


     


    

 


(hh) Neither the Company nor any of its subsidiaries nor, to
the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is
aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt
Practices Act of 1977, as amended, and the rules and regulations thereunder (the “Foreign Corrupt Practices Act”),
including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance
of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or
authorization of the giving of anything of value to any “foreign official” (as such term is defined in the Foreign
Corrupt Practices Act) or any foreign political party or official thereof or any candidate for foreign political office, in contravention
of the Foreign Corrupt Practices Act; and the Company, its subsidiaries and, to the knowledge of the Company, its affiliates have
conducted their businesses in compliance in all material respects with the Foreign Corrupt Practices Act and have instituted and
maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
in all material respects therewith.


 


(ii) Neither the Company nor any of its subsidiaries nor, to
the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is
currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(“OFAC”); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.


 


(jj)The operations of the Company and its subsidiaries are and
have been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements
of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the “United and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001” (the “Patriot Act”) or the
money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any governmental agency.


 


(kk) No labor problem or dispute with the employees of the Company
or any of its subsidiaries exists, or, to the Company’s knowledge, is threatened or imminent, which would reasonably be expected
to result in a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the
Company or any of its subsidiaries plans to terminate employment with the Company or any of its subsidiaries. Except for matters
which would not, individually or in the aggregate, result in a Material Adverse Effect, neither the Company nor any of its subsidiaries
has engaged in any unfair labor practice, and (i) there is (A) no unfair labor practice complaint pending or, to the Company’s
knowledge, threatened against the Company or any of its subsidiaries before the National Labor Relations Board, and no grievance
or arbitration proceeding arising out of or under collective bargaining agreements is pending or to the Company’s knowledge,
threatened, (B) no strike, labor dispute, slowdown or stoppage pending or, to the Company’s knowledge, threatened against
the Company or any of its subsidiaries and (C) no union representation dispute currently existing concerning the employees of the
Company or any of its subsidiaries and (ii) to the Company’s knowledge, (A) no union organizing activities are currently
taking place concerning the employees of the Company or any of its subsidiaries and (B) there has been no violation of any federal,
state, local or foreign law relating to discrimination in the hiring, promotion or pay of employees, any applicable wage or hour
laws or any provision of the Employee Retirement Income Security Act of 1974 (“ERISA”) or the rules and regulations
promulgated thereunder concerning the employees of the Company or any of its subsidiaries.


 




    8 


     


    

 


(ll) Except as disclosed in the Registration Statement, the
Time of Sale Information and the Prospectus (or any amendment or supplement thereto), the Company and its subsidiaries (i) are
in compliance with any and all applicable federal, state, local and foreign laws and regulations relating to the protection of
human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental
Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or
approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals
or failure to comply with the terms and conditions of such permits, licenses or other approvals would not, individually or in the
aggregate, have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has been named as a “potentially
responsible party” under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended. Neither
the Company nor any of its subsidiaries owns, leases or occupies any property that appears on any list of hazardous sites compiled
by any state or local governmental agency. There are no costs or liabilities associated with Environmental Laws (including, without
limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental
Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third
parties) which would, individually or in the aggregate, result in a Material Adverse Effect.


 


(mm) Except as otherwise disclosed in the Time of Sale Information
and the Prospectus, each of the Company and its subsidiaries owns and has full right, title and interest in and to, or has valid
licenses to use, each material trade name, trademark, service mark, patent, copyright, approval, trade secret and other similar
rights (collectively “Intellectual Property”) under which the Company and its subsidiaries conduct all or any
material part of its business, and the Company has not created any lien or encumbrance on, or granted any right or license with
respect to, any such Intellectual Property except where the failure to own or obtain a license or right to use any such Intellectual
Property would not have a Material Adverse Effect; there is no material claim pending against the Company or its subsidiaries with
respect to any Intellectual Property, and the Company and its subsidiaries have not received notice or otherwise become aware that
any Intellectual Property that it uses or has used in the conduct of its business infringes upon or conflicts with the rights of
any third party. Neither the Company nor any of its subsidiaries has become aware that any material Intellectual Property that
it uses or has used in the conduct of its business infringes upon or conflicts with the rights of any third party.


 


(nn) The Company has procured Lock-Up Agreements, in the form
of Exhibit C attached hereto, from each of the individuals set forth on Schedule D.


 


(oo) To the Company’s knowledge, there are no affiliations
or associations between (i) any member of FINRA and (ii) the Company or any of the Company’s officers, directors, 5% or greater
security holders or any beneficial owner of the Company’s unregistered equity securities that were acquired at any time on
or after the 180th day immediately preceding the date the Registration Statement was initially filed with the Commission, except
as otherwise disclosed in the Registration Statement, the Time of Sale Information, the Prospectus or the FINRA Questionnaires
previously furnished to the Representative.


 


(pp) The Company and each of its subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary
in the businesses in which it is engaged; and neither the Company nor any of its subsidiaries has reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a comparable cost.


 


(qq) The Company and its subsidiaries and any “employee
benefit plan” (as defined under ERISA) established or maintained by the Company, its subsidiaries or their “ERISA Affiliates”
(as defined below) are in compliance in all material respects with ERISA and all other applicable state and federal laws. “ERISA
Affiliate” means, with respect to the Company or a subsidiary, any member of any group or organization described in Sections
414(b), (c), (m) or (o) of the Code of which the Company or such subsidiary is a member. No “reportable event” (as
defined in ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established
or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No “employee benefit plan” established
or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were
terminated, would have any “amount of unfunded benefit liabilities” (as defined in ERISA). Neither the Company, its
subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of
ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975
or 4980B of the Code. Each “employee benefit plan” established or maintained by the Company, its subsidiaries or any
of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred,
whether by action or failure to act, that would cause the loss of such qualification.


 




    9 


     


    

 


(rr) Except as otherwise disclosed in the Time of Sale Information
and the Prospectus, each of the Company and its subsidiaries has all registrations, permits, licenses, approvals, consents and
authorizations (“Regulatory Permits”) required by the United States Food and Drug Administration (the “FDA”)
or any other regulatory authority engaged in the regulation of medical devices such as those being developed by the Company (“Regulatory
Authority”). The Company is in material compliance with the requirements of the Regulatory Permits, and all of the Regulatory
Permits are valid and in full force and effect; the Company has not received any notice of proceedings relating to the revocation,
termination, modification or impairment of rights of any of the Regulatory Permits, that, individually or in the aggregate, if
the subject of an unfavorable decision, ruling or finding could reasonably be expected to result in a Material Adverse Effect;
the Company has not failed to file with the FDA or any other Regulatory Authority any required application, submission, report,
document, or notice, and all such filings were in material compliance with applicable laws when filed and have been supplemented
as necessary to remain in material compliance with applicable laws and no material deficiencies have been asserted by the FDA or
any other Regulatory Authority with respect to any such filings, in each case, except as otherwise disclosed in the Time of Sale
Information and the Prospectus.


 


(ss) The non-clinical studies and, as applicable, clinical trials
conducted by the Company, and each of its subsidiaries have been and, if still pending, are being conducted, in all material respects,
in accordance with experimental protocols and procedures pursuant to all applicable laws and Regulatory Permits, and the results
of such studies and clinical trials described in the Time of Sale Information and the Prospectus are accurate and fairly present,
in all material respects, the data derived from such studies and clinical trials; any studies and clinical trials conducted by
the Company, or its subsidiaries, if still pending, are being conducted in all material respects in accordance with applicable
professional and scientific standards and the applicable requirements of the FDA and other Regulatory Authorities; neither the
Company nor any subsidiary has received any notice or correspondence from the FDA nor any Regulatory Authority requiring the termination,
suspension or modification of any such study or clinical trial; and the Company is not aware of any study or clinical trial, the
results of which the Company believes reasonably call into question the results described or referred to in the Time of Sale Information
and the Prospectus.


 


4. FURTHER AGREEMENTS OF THE COMPANY. The Company agrees
with the Placement Agents:


 


(a) To prepare the Rule 462(b) Registration Statement, if necessary,
in a form approved by the Representative and file such Rule 462(b) Registration Statement with the Commission on the date hereof;
to prepare the Prospectus in a form approved by the Representative containing information previously omitted at the time of effectiveness
of the Registration Statement in reliance on rules 430A, 430B and 430C of the Rules and Regulations and to file such Prospectus
pursuant to Rule 424(b) of the Rules and Regulations not later than the second (2nd) business day following the execution
and delivery of this Agreement or, if applicable, such earlier time as may be required by Rule 430A of the Rules and Regulations;
to notify the Representative immediately of the Company’s intention to file or prepare any supplement or amendment to any
Registration Statement or to the Prospectus in connection with this Offering and to make no amendment or supplement to the Registration
Statement, the Time of Sale Information or to the Prospectus to which the Representative shall reasonably object by notice to the
Company after a reasonable period to review; to advise the Representative, promptly after it receives notice thereof, of the time
when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the Time of Sale Information
or the Prospectus or any amended Prospectus has been filed and to furnish the Representative copies thereof; to file promptly all
material required to be filed by the Company with the Commission pursuant to Rule 433(d) or 163(b)(2), as the case may be, of the
Rules and Regulations; to file promptly all reports and any definitive proxy or information statements required to be filed by
the Company with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the
Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules
and Regulations) is required in connection with the Offering or sale of the Securities; to advise the Representative, promptly
after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending
the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus, of the suspension of the qualification
of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose,
or of any request by the Commission for the amending or supplementing of the Registration Statement, the Time of Sale Information
or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing
or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such
qualification, and promptly to use its best efforts to obtain the withdrawal of such order.


 




    10 


     


    

 


(b) The Company represents and agrees that, it has not made,
and unless it obtains the prior consent of the Representative, it will not make, any offer relating to the Units that would constitute
a “free writing prospectus” as defined in Rule 405 of the Rules and Regulations (each, a “Permitted Free Writing
Prospectus”); provided that the prior written consent of the Representative hereto shall be deemed to have been
given in respect of the Issuer Free Writing Prospectus(es) included in Schedule A hereto. The Company represents that it
has treated and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply with
the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus, including
the requirements relating to timely filing with the Commission, legending and record keeping and will not take any action that
would result in the Placement Agents or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules
and Regulations a free writing prospectus prepared by or on behalf of such Placement Agent that such Placement Agent otherwise
would not have been required to file thereunder.


 


(c) If at any time when a Prospectus relating to the Securities
is required to be delivered under the Securities Act, any event occurs or condition exists as a result of which the Prospectus,
as then amended or supplemented, would include any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading, or the Registration
Statement, as then amended or supplemented, would include any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein not misleading, or if for any other reason it is necessary at any time to amend or supplement
any Registration Statement or the Prospectus to comply with the Securities Act or the Exchange Act, the Company will promptly notify
the Representative, and upon the Representative’s request, the Company will promptly prepare and file with the Commission,
at the Company’s expense, an amendment to the Registration Statement or an amendment or supplement to the Prospectus that
corrects such statement or omission or effects such compliance and will deliver to the Placement Agents, without charge, such number
of copies thereof as the Placement Agents may reasonably request. The Company consents to the use of the Prospectus or any amendment
or supplement thereto by the Placement Agents.


 


(d) If the Time of Sale Information is being used to solicit
offers to buy the Securities at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur
as a result of which, in the judgment of the Company or in the reasonable opinion of the Representative, it becomes necessary to
amend or supplement the Time of Sale Information in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading, or to make the statements therein not conflict with the information contained or incorporated
by reference in the Registration Statement then on file and not superseded or modified, or if it is necessary at any time to amend
or supplement the Time of Sale Information to comply with any law, the Company promptly will either (i) prepare, file with
the Commission (if required) and furnish to the Placement Agents and any dealers an appropriate amendment or supplement to the
Time of Sale Information or (ii) prepare and file with the Commission an appropriate filing under the Exchange Act which shall
be incorporated by reference in the Time of Sale Information so that the Time of Sale Information as so amended or supplemented
will not, in the light of the circumstances under which they were made, be misleading or conflict with the Registration Statement
then on file, or so that the Time of Sale Information will comply with law.


 


(e) If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted
or will conflict with the information contained in the Registration Statement, Preliminary Prospectus or Prospectus, including
any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof and not superseded or
modified or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading, the Company has promptly notified or will promptly notify the Representative so that any use of
the Issuer Free Writing Prospectus may cease until it is amended or supplemented and has promptly amended or will promptly amend
or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement
or omission. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance
upon, and in conformity with, written information furnished to the Company by the Representative by or on behalf of the Placement
Agents specifically for inclusion therein, which information the parties hereto agree is limited to the Placement Agents’
Information (as defined in Section 3(d)).


 




    11 


     


    

 


(f) To the extent not available on the Commission’s EDGAR
system or any successor system, to furnish promptly to the Placement Agents and to counsel for the Placement Agents a signed copy
of the Registration Statement as originally filed with the Commission, and of each amendment thereto filed with the Commission,
including all consents and exhibits filed therewith.


 


(g) To the extent not available on the Commission’s EDGAR
system or any successor system, to deliver promptly to the Representative in New York City such number of the following documents
as the Representative shall reasonably request: (i) conformed copies of the Registration Statement as originally filed with
the Commission (in each case excluding exhibits), (ii) each Preliminary Prospectus (if any), (iii) any Issuer Free Writing
Prospectus, (iv) the Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii) and (iv) of
this paragraph (g) to be made not later than 10:00 A.M., New York time, on the business day following the execution
and delivery of this Agreement), (v) conformed copies of any amendment to the Registration Statement (excluding exhibits),
(vi) any amendment or supplement to the Time of Sale Information or the Prospectus (the delivery of the documents referred
to in clauses (v) and (vi) of this paragraph (g) to be made not later than 10:00 A.M., New York City time,
on the business day following the date of such amendment or supplement) and (vii) any document incorporated by reference in
the Time of Sale Information or the Prospectus (excluding exhibits thereto) (the delivery of the documents referred to in clause
(vi) of this paragraph (g) to be made not later than 10:00 A.M., New York City time, on the business day following
the date of such document).


 


(h) To make generally available to its stockholders as soon
as practicable, but in any event not later than eighteen (18) months after the effective date of each Registration Statement
(as defined in Rule 158(c) of the Rules and Regulations), an earnings statement of the Company and its subsidiaries (which need
not be audited) complying with Section 11(a) of the Securities Act and the Rules and Regulations (including, at the option
of the Company, Rule 158).


 


(i) The Company will cooperate with you and counsel for the
Representative in connection with the registration or qualification of the Securities under the securities or Blue Sky laws of
such jurisdictions as you may reasonably designate and will file such consents to service of process or other documents as may
be reasonably necessary in order to effect and maintain such registration or qualification for so long as required to complete
the distribution of the Securities; provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction
where it is not now so qualified or to take any action that would subject it to general service of process in suits, other than
those arising out of the offering or sale of the Securities, as contemplated by this Agreement and the Prospectus, in any jurisdiction
where it is not now so subject. In the event that the qualification of the Securities in any jurisdiction is suspended, the Company
shall so advise you promptly in writing. The Company will use its reasonable best efforts to qualify or register the Conversion
Shares and Warrant Shares for sale in non-issuer transactions under (or obtain exemptions from the application of) the Blue Sky
laws of each state where necessary to permit market making transactions and secondary trading and will comply with such Blue Sky
laws and will continue such qualifications, registrations and exemptions in effect until the earlier of such time as the Common
Stock is listed or quoted, as the case may be, on the New York Stock Exchange, the American Stock Exchange or quoted on the NASDAQ
Stock Market, or three (3) years from the date hereof, provided that if the Company obtains and keeps current a listing of its
Common Stock in the Standard & Poor’s Corporation Records Services or Mergent’s Industrial Manual it shall be deemed
to have satisfied such requirement, except that Mergent’s OTC Industrial Manual is not sufficient for these purposes. Unless
the Common Stock is listed or quoted, as the case may be, on the New York Stock Exchange, the American Stock Exchange or quoted
on the NASDAQ Stock Market, the Company shall at the beginning of each fiscal quarter, provide you with a written report detailing
those states in which the Conversion Shares and Warrant Shares may be traded in non-issuer transactions under the Blue Sky laws
of the fifty States for a period of three (3) years after the date hereof.


 


(j) Upon request, during the period of three (3) years
from the date hereof, to the extent not available on the Commission’s EDGAR system or any successor system, to deliver to
the Placement Agents, as soon as they are available (i) copies of all reports or other communications furnished to stockholders,
and (ii) copies of any reports and financial statements furnished or filed with the Commission or any national securities
exchange or automatic quotation system on which the Common Stock is listed or quoted.


 




    12 


     


    

 


(k) For a period commencing on the date hereof and ending on
the 90th day after the date of the Prospectus (the “Lock-Up Period”), the Company agrees not to, directly or
indirectly, and other than in connection with an Exempt Issuance (as defined in the Securities Purchase Agreement), (1) offer for
sale, sell, pledge or otherwise dispose of (or enter into any transaction or device that is designed to do any of the foregoing)
any shares of Common Stock or securities convertible into or exchangeable for Common Stock (other than Common Stock issued pursuant
to employee benefit plans, qualified stock option plans or other employee compensation plans existing on the date hereof or pursuant
to currently outstanding options, warrants or rights or Common Stock issued pursuant to other agreements existing on the date hereof
and disclosed in the Registration Statement or the Prospectus), or sell or grant options, rights or warrants with respect to any
shares of Common Stock or securities convertible into or exchangeable for Common Stock (other than the grant of options, warrants
or rights pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans existing on the
date hereof), (2) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the
economic benefits or risks of ownership of such shares of Common Stock, whether any such transaction described in clause (1) or
(2) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise, (3) file or cause to be filed
a registration statement, including any amendments, with respect to the registration of any shares of Common Stock or securities
convertible, exercisable or exchangeable into Common Stock or any other securities of the Company (other than the filing of a registration
statement on Form S-8, including any amendments thereto, or any post effective amendments or prospectus supplements with respect
to the Company’s registration statement on Form S-1 (File No. 333-195783), effective as of the date hereof) or (4) publicly
disclose the intention to do any of the foregoing, in each case without the prior written consent of the Representative, and to
cause each individual set forth on Schedule D to furnish to the Representative, prior to the Closing Date, a letter or letters,
substantially in the form of Exhibit C hereto (the “Lock-Up Agreements”).


 


(l) To the extent not available on EDGAR, to supply the Representative
with copies of all correspondence to and from, and all documents issued to and by, the Commission in connection with the registration
of the Securities under the Securities Act or the Registration Statement, any Preliminary Prospectus or the Prospectus, or any
amendment or supplement thereto.


 


(m) Prior to the Closing Date, not to issue any press release
or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial
or otherwise, or earnings, business affairs or business prospects (except for routine marketing communications in the ordinary
course of business and consistent with the past practices of the Company, and of which the Representative is notified), without
the prior written consent of the Representative, unless in the judgment of the Company and its counsel, and after notification
to the Representative, such press release or communication is required by law or applicable stock exchange rules.


 


(n) Until the Representative shall have notified the Company
of the completion of the Offering, that the Company will not, and will cause its affiliated purchasers (as defined in Regulation
M under the Exchange Act) not to, either alone or with one or more other persons, bid for or purchase, for any account in which
it or any of its affiliated purchasers has a beneficial interest, any Securities, or attempt to induce any person to purchase any
Securities; and not to, and to cause its affiliated purchasers not to, make bids or purchases for the purpose of creating actual,
or apparent, active trading in or of raising the price of the Securities.


 


(o) Not to take any action prior to the Closing Date, which
would require the Prospectus to be amended or supplemented pursuant to Section 4.


 


(p) To at all times comply with all applicable provisions of
the Sarbanes-Oxley Act in effect from time to time.


 


(q) To apply the net proceeds from the sale of the Securities
as set forth in the Registration Statement, the Time of Sale Information and the Prospectus under the heading “Use of Proceeds.”


 


(r) To use its best efforts to assist the Placement Agents with
any filings with, and to obtain clearance from, FINRA.


 


(s) To use its best efforts to list, subject to notice of issuance,
effect and maintain the quotation and listing of the Common Stock on the OTCBB.


 




    13 


     


    

 


(t) To timely file with OTCBB all documents and notices required
by the OTCBB of companies that have or will issue securities that are quoted on the OTCBB.


 


(u) To use its best efforts to do and perform all things required
to be done or performed under this Agreement by the Company prior to the Closing Date, and to satisfy all conditions precedent
to the delivery of the Securities.


 


5. PAYMENT OF EXPENSES. Whether or not the transactions
contemplated hereby are consummated or this Agreement becomes effective or is terminated, the Company agrees to pay or cause to
be paid the following: (i) the fees, disbursements and expenses of the Company’s counsel and accountants in connection with
the registration of the sale of Securities under the Act and all other expenses in connection with the preparation, printing and
filing of the Registration Statement and the Prospectus and amendments and supplements thereto and the mailing and delivering of
copies thereof and of any Preliminary Prospectus; (ii) the printing and delivery (including postage, air freight charges and charges
for counting and packaging) of such copies of the Registration Statement, the Prospectus, each Preliminary Prospectus, the Time
of Sale Information, the Blue Sky memoranda, this Agreement, the Selected Dealers Agreement and all amendments or supplements to
any of them as may be reasonably requested for use in connection with the offering and sale of the Securities; (iii) consistent
with the provisions of Section 4(i), all expenses in connection with the qualification of the Securities for offering and sale
under state securities laws or Blue Sky laws; (iv) the filing fees incident to securing any required review by FINRA of the fairness
of the terms of the sale of the Securities and the reasonable fees and disbursements of the Placement Agents’ counsel relating
thereto; (v) the fees and expenses associated with quoting the Common Stock on the OTCBB; (vi) the cost of preparing stock certificates;
(vii) the costs and charges of any transfer agent or registrar; (viii) the cost of the tax stamps, if any, in connection with the
issuance and delivery of the Securities; (ix) all other fees, costs and expenses referred to in Part II, Item 14 of the Registration
Statement; and (x) the transportation, lodging, graphics and other expenses incidental to the Company’s preparation for and
participation in the “roadshow” for the offering contemplated hereby. Except as provided in this Section 5 and in Section
7 hereof, the Placement Agents shall pay their own expenses, including the fees and disbursements of their counsel, provided however
that upon the closing of the sale of Securities, the Company shall reimburse the Placement Agents for fees, disbursements and other
charges of counsel to the Placement Agents in an amount not to exceed $62,500.


 


6. CONDITIONS TO THE OBLIGATIONS OF THE PLACEMENT AGENTS,
AND THE SALE OF THE SECURITIES. The respective obligations of the Placement Agents hereunder, and the closing of the sale of
the Units, are subject to each of the following terms and conditions:


 


(a) All filings require by Rules 424(b), 430B and 462 under
the Act shall have been timely made.


 


(b) You shall be reasonably satisfied that since the respective
dates as of which information is given in the Registration Statement, the Time of Sale Information and Prospectus, (i) there shall
not have been any change in the capital stock of the Company or any material change in the indebtedness (other than in the ordinary
course of business) of the Company, (ii) except as set forth or contemplated by the Registration Statement, the Time of Sale Information
or the Prospectus, no material oral or written agreement or other transaction shall have been entered into by the Company that
is not in the ordinary course of business or that could reasonably be expected to result in a material reduction in the future
earnings of the Company, (iii) no loss or damage (whether or not insured) to the property of the Company shall have been sustained
that had or could reasonably be expected to have a Material Adverse Effect, (iv) no legal or governmental action, suit or proceeding
affecting the Company or any of its properties that is material to the Company or that affects or could reasonably be expected
to affect the transactions contemplated by this Agreement shall have been instituted or threatened and (v) there shall not have
been any material change in the condition (financial or otherwise), business, management, results of operations or prospects of
the Company or its subsidiaries that makes it impractical or inadvisable in your judgment to proceed with the public offering or
purchase of the Securities as contemplated hereby.


 


(c) You shall have received on the Closing Date an opinion of
Nutter McClennen & Fish LLP, counsel to the Company, addressed to the Representative, substantially in the form heretofore
approved by you.


 


In rendering such opinion, counsel may rely,
to the extent they deem such reliance proper, as to matters of fact upon certificates of officers of the Company and of government
officials, provided that counsel shall state their belief that they and you are justified in relying thereon. Copies of all such
certificates shall be furnished to you and your counsel on the Closing Date.


 




    14 


     


    

 


 


(d) You
shall have received on the Closing Date an opinion of Diederiks & Whitelaw, PLC, special intellectual property counsel to the
Company, addressed to the Representative, substantially in the form heretofore approved by you. 


 


(e) You shall have received on the Closing Date an opinion of
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., as counsel for the Placement Agents, dated the Closing Date with respect to
the issuance and sale of the Securities, the Registration Statement and other related matters as you may reasonably request, and
the Company and its counsel shall have furnished to your counsel such documents as they may reasonably request for the purpose
of enabling them to pass upon such matters.


 


(f) You shall have received letters addressed to you and dated
the date hereof and the Closing Date, from (i) the firm of OUM & Co. LLP, independent certified public accountants and (ii)
the Chief Financial Officer of the Company, substantially in the forms heretofore approved by you.


 


(g) (i) No stop order suspending the effectiveness of the Registration
Statement shall have been issued by the Commission and no proceedings for that purpose shall be pending or, to the knowledge of
the Company, shall be threatened or contemplated by the Commission at or prior to the Closing Date; (ii) to the knowledge of the
Company no order suspending the effectiveness of the Registration Statement or the qualification or registration of the Securities
under the securities or Blue Sky laws of any jurisdiction shall be in effect and no proceeding for such purpose shall be pending
or, to the knowledge of the Company, threatened or contemplated by the authorities of any jurisdiction; (iii) any request for additional
information on the part of the staff of the Commission or any such authorities shall have been complied with to the satisfaction
of the staff of the Commission or such authorities; (iv) after the date hereof, no amendment or supplement to the Registration
Statement or the Prospectus shall have been filed unless a copy thereof was first submitted to you and you did not object thereto
in good faith; and (v) all of the representations and warranties of the Company contained in this Agreement shall be true and correct
in all material respects (except for such representations and warranties qualified by materiality, which representations and warranties
shall be true and correct in all respects) on and as of the date hereof and on and as of the Closing Date, as if made on and as
of the Closing Date, and you shall have received a certificate, dated the Closing Date and signed by the chief executive officer
and the chief financial officer of the Company (or such other officers as are acceptable to you) to the effect set forth in this
Section 6(g) and in Sections 6(b) and 6(i) hereof.


 


(h) You shall have received on the Closing Date a certificate
of the Company signed by the Secretary of the Company, dated the Closing Date certifying: (i) that each of the Company’s
articles of incorporation and bylaws is true and complete, has not been modified and is in full force and effect; (ii) that the
resolutions of the Company’s board of directors relating to the offering of the Securities are in full force and effect and
have not been modified; and (iii) as to the incumbency of the officers of the Company. The documents referred to in such certificate
shall be attached to such certificate.


 


(i) The Company shall not have failed in any material respect
at or prior to the Closing Date to have performed or complied with any of its agreements herein contained and required to be performed
or complied with by it hereunder at or prior to the Closing Date.


 


(j) The Company shall have furnished or caused to have been
furnished to you such further certificates and documents as you shall have reasonably requested.


 


(k) At or prior to the Closing Date, you shall have received
the written Lock-Up Agreements from each of the individuals set forth on Schedule D.


 


(l) At or prior to the date of this Agreement, you shall have
received a letter from the Corporate Financing Department of FINRA confirming that such Department has determined to raise no objections
with respect to the fairness or reasonableness of the placement agency terms and arrangements of the offering contemplated hereby.


 




    15 


     


    

 


(n) The Company shall have entered into Securities Purchase
Agreement with each of the Purchasers and such agreements shall be in full force and effect.


 


(o) The Company shall have filed the Certificate of Designation
with the Secretary of State of the State of Nevada.


 


(p) The Company shall have furnished to the Representative such
further information, good standing certificates of the Company, opinions, certificates (including a Secretary’s Certificate),
letters or such other documents as the Representative shall have reasonably requested.


 


All opinions, letters, evidence and certificates mentioned above
or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance
reasonably satisfactory to counsel for the Placement Agents.


 


7. INDEMNIFICATION AND CONTRIBUTION.


 


Subject to the limitations in this paragraph below, the Company
agrees to indemnify and hold harmless you and each other Placement Agent, the directors, officers, employees and agents of each
Placement Agent, and each person, if any, who controls any Placement Agent within the meaning of Section 15 of the Act or Section
20 of the Exchange Act (collectively, the “Placement Agent Indemnified Parties,” and each a “Placement
Agent Indemnified Party”) from and against any and all losses, claims, damages, liabilities and expenses, including reasonable
costs of investigation and attorneys’ fees and expenses (collectively, “Damages”) arising out of or based
upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, in the Registration
Statement, the Time of Sale Information, any Issuer Free Writing Prospectus or the Prospectus or in any amendment or supplement
thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made not misleading, except to the extent that any
such Damages arise out of or are based upon an untrue statement or omission or alleged untrue statement or omission that has been
made therein or omitted therefrom in reliance upon and in conformity with the Placement Agents’ Information or (ii) any inaccuracy
in or breach of the representations and warranties of the Company contained herein or any failure of the Company to perform its
obligations hereunder or under law; provided, however, that with respect to any untrue statement or omission made in any Preliminary
Prospectus, the indemnity agreement contained in this paragraph shall not inure to the benefit of any Placement Agent (or to the
benefit of any person controlling such Placement Agent or to any officer, director, employee or agent of any Placement Agent) if
both (A) such Placement Agent failed to deliver a copy of the Time of Sale Information to the person asserting such Damages at
or prior to the written confirmation of the sale of such Securities to such person as required by the Act and (B) the untrue statement
or omission in the Preliminary Prospectus was corrected in the Time of Sale Information. This indemnification shall be in addition
to any liability that the Company may otherwise have.


 


If any action or claim shall be brought against any Placement
Agent or any person controlling any Placement Agent in respect of which indemnity may be sought against the Company, such Placement
Agent or such controlling person shall promptly notify in writing the party(s) against whom indemnification is being sought (the
“indemnifying party” or “indemnifying parties”), and such indemnifying party(s) shall assume the defense
thereof, including the employment of counsel reasonably acceptable to such Placement Agent or such controlling person and the payment
of all reasonable fees of and expenses incurred by such counsel. Such Placement Agent or any such controlling person shall have
the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Placement Agent or such controlling person, unless (i) the indemnifying party(s) has (have)
agreed in writing to pay such fees and expenses, (ii) the indemnifying party(s) has (have) failed to assume the defense and employ
counsel reasonably acceptable to the Placement Agent or such controlling person or (iii) the named parties to any such action (including
any impleaded parties) include both such Placement Agent or such controlling person and the indemnifying party(s), and such Placement
Agent or such controlling person shall have been advised by its counsel that one or more legal defenses may be available to the
Placement Agent that may not be available to the Company, or that representation of such indemnified party and any indemnifying
party(s) by the same counsel would be inappropriate under applicable standards of professional conduct (whether or not such representation
by the same counsel has been proposed) due to actual or potential differing interests between them (in which case the indemnifying
party(s) shall not have the right to assume the defense of such action on behalf of such Placement Agent or such controlling person
(but the Company shall not be liable for the fees and expenses of more than one counsel for the Placement Agents and such controlling
persons)). The indemnifying party(s) shall not be liable for any settlement of any such action effected without its (their several)
written consent, but if settled with such written consent, or if there be a final judgment for the plaintiff in any such action,
the indemnifying party(s) agree(s) to indemnify and hold harmless any Placement Agent and any such controlling person from and
against any loss, claim, damage, liability or expense by reason of such settlement or judgment, but in the case of a judgment only
to the extent stated in the first paragraph of this Section 7.


 




    16 


     


    

 


Each Placement Agent agrees, severally and not jointly, to indemnify
and hold harmless the Company, its directors, its officers who sign the Registration Statement and any person who controls the
Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act (collectively, the “Company Indemnified
Parties,” and each a “Company Indemnified Party”), to the same extent as the foregoing several indemnity
from the Company to each Placement Agent, but only with respect to information furnished in writing by or on behalf of such Placement
Agent through you expressly for use in the Registration Statement, the Prospectus, the Time of Sale Information, any Issuer Free
Writing Prospectus or any Preliminary Prospectus, or any amendment or supplement thereto. If any action or claim shall be brought
or asserted against the Company, any of its directors, any of its officers or any such controlling person based on the Registration
Statement, the Prospectus, the Time of Sale Information or any Preliminary Prospectus, or any amendment or supplement thereto,
and in respect of which indemnity may be sought against any Placement Agent pursuant to this paragraph, such Placement Agent shall
have the rights and duties given to the Company by the immediately preceding paragraph (except that if the Company shall have assumed
the defense thereof such Placement Agent shall not be required to do so, but may employ separate counsel therein and participate
in the defense thereof, but the fees and expenses of such counsel shall be at such Placement Agent’s expense), and the Company,
its directors, any such officers and any such controlling persons, shall have the rights and duties given to the Placement Agents
by the immediately preceding paragraph.


 


In any event, the Company will not, without the prior written
consent of the Representative, settle or compromise or consent to the entry of any judgment in any proceeding or threatened claim,
action, suit or proceeding in respect of which indemnification may be sought hereunder (whether or not the Representative or any
person who controls the Representative within the meaning of Section 15 of the Act or Section 20 of the Exchange Act is a party
to such claim, action, suit or proceeding) unless such settlement, compromise or consent includes an unconditional release of all
Placement Agents and such controlling persons from all liability arising out of such claim, action, suit or proceeding.


 


If the indemnification provided for in this Section 7 is unavailable
or insufficient for any reason whatsoever to an indemnified party in respect of any Damages referred to herein, then an indemnifying
party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by such indemnified party
as a result of such Damages (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on
the one hand, and the Placement Agents on the other hand, from the offering and sale of the Securities or (ii) if the allocation
provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i) above but also the relative and several fault of the Company on the one hand, and the Placement
Agents on the other hand, in connection with the statements or omissions that resulted in such Damages as well as any other relevant
equitable considerations. The relative and several benefits received by the Company on the one hand, and the Placement Agents on
the other hand, shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses)
received by the Company bear to the total fees and commissions received by the Placement Agents, in each case as set forth in the
table on the cover page of the Prospectus. The relative fault of the Company on the one hand, and the Placement Agents on the other
hand, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand, or
by the Placement Agents on the other hand and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.


 




    17 


     


    

 


The Company and the Placement Agents agree that it would not
be just and equitable if contribution pursuant to this Section 7 was determined by a pro rata allocation (even if the Placement
Agents were treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable
considerations referred to in the immediately preceding paragraph. The amount paid or payable by an indemnified party as a result
of the Damages referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending
any such action or claim. Notwithstanding the provisions of this Section 7, in no event shall any indemnity by any Placement Agent
under this Section 7 exceed the total fees and commission received by such Placement Agent in connection with the Offering. No
person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.


 


Any Damages for which an indemnified party is entitled to indemnification
or contribution under this Section 7 shall be paid by the indemnifying party to the indemnified party as Damages are incurred after
receipt of reasonably itemized invoices therefor. The indemnity, contribution and reimbursement agreements contained in this Section
7 and the representations and warranties of the Company set forth in this Agreement shall remain operative and in full force and
effect, regardless of (i) any investigation made by or on behalf of any Placement Agent or any person controlling any Placement
Agent, the Company, its directors or officers or any person controlling the Company, (ii) acceptance of any Securities and payment
therefor hereunder and (iii) any termination of this Agreement. A successor to any Placement Agent or any person controlling any
Placement Agent, or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits
of the indemnity, contribution and reimbursement agreements contained in this Section 7.


 


8. TERMINATION. This Agreement shall be subject to termination
in your absolute discretion, without liability on the part of any Placement Agent to the Company, by notice to the Company, if
prior to the Closing Date, in your sole judgment, (i) trading in the Company’s Common Stock shall have been suspended by
the Commission or quotation of the Company’s Common Stock shall have been suspended by the OTCBB, (ii) quotation in securities
generally on the OTCBB or trading in securities generally on the New York Stock Exchange or the NASDAQ Stock Market shall have
been suspended or materially limited, or minimum or maximum prices shall have been generally established on such quotations service
or exchange, or additional material governmental restrictions, not in force on the date of this Agreement, shall have been imposed
upon trading in securities generally by any such exchange or the OTCBB or by order of the Commission or any court or other governmental
authority, (iii) a general moratorium on commercial banking activities shall have been declared by either federal or New York State
authorities or (iv) there shall have occurred any outbreak or escalation of hostilities or other international or domestic calamity,
crisis or change in political, financial or economic conditions or other material event the effect of which on the financial markets
of the United States is such as to make it, in your judgment, impracticable or inadvisable to market the Securities or to enforce
contracts for the sale of the Securities. Notice of such cancellation shall be promptly given to the Company and its counsel by
telegraph, telecopy or telephone and shall be subsequently confirmed by letter.


 


9. REIMBURSEMENT OF PLACEMENT AGENTS’ EXPENSES.
Notwithstanding anything to the contrary in this Agreement, if (a) this Agreement shall have been terminated pursuant to Section 8,
(b) the Company shall fail to tender the Units for delivery to the Purchasers for any reason not permitted under this Agreement,
(c) the Purchasers shall decline to purchase the Units for any reason permitted under the Securities Purchase Agreement or
(d) the sale of the Units is not consummated because any condition to the obligations of the Placement Agents set forth herein
is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement herein or
to satisfy any condition or to comply with the provisions hereof, then, in addition to the payment of out-of-pocket expenses in
accordance with Section 5, the Company shall reimburse the Placement Agents for the fees and expenses of the Placement
Agents’ counsel and for such other accountable out-of-pocket expenses as shall have been reasonably incurred by them in connection
with this Agreement and the proposed purchase of the Securities, and upon demand the Company shall pay the full amount thereof
to the Representative on behalf of the Placement Agents.


 


10. ABSENCE OF FIDUCIARY RELATIONSHIP. The Company acknowledges
and agrees that:


 


(a) Each Placement Agent’s responsibility to the Company
is solely contractual in nature, each Placement Agent has been retained solely to act as an Placement Agent in connection with
the Offering and no fiduciary, advisory or agency relationship between the Company and such Placement Agent has been created in
respect of any of the transactions contemplated by this Agreement, irrespective of whether Ladenburg or Trout has advised or is
advising the Company on other matters;


 




    18 


     


    

 


(b) the price of the Units set forth in this Agreement was established
by the Company following discussions and arms-length negotiations with the Representative, and the Company is capable of evaluating
and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;


 


(c) it has been advised that Ladenburg and Trout, and each of
their affiliates, are engaged in a broad range of transactions which may involve interests that differ from those of the Company
and that the Placement Agents have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship; and


 


(d) it waives, to the fullest extent permitted by law, any claims
it may have against the Placement Agents for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that the Placement
Agents shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim or to any
person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors
of the Company.


 


11. SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT.
This Agreement shall inure to the benefit of and be binding upon the several Placement Agents, the Company, and their respective
successors and assigns. Notwithstanding the foregoing, the determination as to whether any condition in Section 6 hereof
shall have been satisfied, and the waiver of any condition in Section 6 hereof, may be made by the Representative in
its sole discretion, and any such determination or waiver shall be binding on each of the Placement Agents and shall not require
the consent of any Placement Agent. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give
any person, other than the persons mentioned in the preceding sentences, any legal or equitable right, remedy or claim under or
in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being
intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that
the representations, warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also be
for the benefit of the Placement Agent Indemnified Parties and the several indemnities of the Placement Agents shall be for the
benefit of the Company Indemnified Parties. It is understood that each Placement Agent’s responsibility to the Company is
solely contractual in nature and the Placement Agents do not owe the Company, or any other party, any fiduciary duty as a result
of this Agreement.


 


12. SURVIVAL OF INDEMNITIES, REPRESENTATIONS, WARRANTIES,
ETC. The respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and
the several Placement Agents, as set forth in this Agreement or made by them respectively, pursuant to this Agreement, shall remain
in full force and effect, regardless of any investigation made by or on behalf of any Placement Agent, the Company or any person
controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any termination of this Agreement,
including without limitation any termination pursuant to Section 8, the payment obligations contained in Section
5, the indemnity and contribution and reimbursement agreements contained in Sections 7 and 9 and the covenants,
representations, warranties set forth in this Agreement shall not terminate and shall remain in full force and effect at all times.


 


13. NOTICES. All statements, requests, notices and agreements
hereunder shall be in writing, and:


 


(a) if to the Representative, shall be delivered or sent by
mail, facsimile transmission or email to Ladenburg Thalmann & Co. Inc., 570 Lexington Avenue, 11th Floor, New York, New York
10022, Attention: Managing Director, Legal, with a copy to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center,
666 Third Avenue, New York, New York 10017, Attention: Ivan K. Blumenthal, Esq.; and


 


(b) if to the Company, shall be delivered or sent by mail, facsimile
transmission or email to: Ekso Bionics Holdings, Inc., 1414 Harbour Way South, Suite 1201, Richmond, California 94804, Attention:
Nathan Harding, Chief Executive Officer, with a copy to Nutter McClennen & Fish LLP, Seaport West, 155 Seaport Blvd., Boston,
Massachusetts 02210-2604, Attention: Michelle Basil


 


provided, however, that any notice to the Placement Agents
pursuant to Section 7 shall be delivered or sent by mail or facsimile transmission to the Representative c/o Ladenburg
Thalmann & Co. Inc. at the address set forth above in this Section 13. Any such statements, requests, notices or
agreements shall take effect at the time of receipt thereof, except that any such statement, request, notice or agreement delivered
or sent by email shall take effect at the time of confirmation of receipt thereof by the recipient thereof.


 




    19 


     


    

 


14. DEFINITION OF CERTAIN TERMS. For purposes of this
Agreement, (a) “business day” means any day on which the New York Stock Exchange, Inc. is open for trading,
(b) “knowledge” means the actual knowledge of the directors and officers of the Company after reasonable
inquiry and (c) “subsidiary” has the meaning set forth in Rule 405 of the Rules and Regulations.


 


15. GOVERNING LAW, AGENT FOR SERVICE AND JURISDICTION.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation
Section 5-1401 of the New York General Obligations Law. No legal proceeding may be commenced, prosecuted or continued in
any court other than the courts of the State of New York located in the City and County of New York or in the United States District
Court for the Southern District of New York, which courts shall have jurisdiction over the adjudication of such matters, and the
Company and the Placement Agents each hereby consent to the jurisdiction of such courts and personal service with respect thereto.
The Company and the Placement Agents each hereby waive all right to trial by jury in any legal proceeding (whether based upon
contract, tort or otherwise) in any way arising out of or relating to this Agreement. The Company agrees that a final judgment
in any such legal proceeding brought in any such court shall be conclusive and binding upon the Company and the Placement Agents
and may be enforced in any other courts in the jurisdiction of which the Company is or may be subject, by suit upon such judgment. 


 


16. PARTIAL UNENFORCEABILITY. The invalidity or unenforceability
of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section,
paragraph, clause or provision hereof. If any section, paragraph, clause or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary
to make it valid and enforceable.


 


17. GENERAL. This Agreement constitutes the entire agreement
of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings
and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine and neuter genders and the
singular and the plural include one another. The section headings in this Agreement are for the convenience of the parties only
and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified, and the observance
of any term of this Agreement may be waived, only by a writing signed by the Company and the Representative.


 


18. RESEARCH ANALYST INDEPENDENCE. The Company acknowledges
that each Placement Agent’s research analysts and research departments are required to be independent from its investment
banking division and are subject to certain regulations and internal policies, and that such Placement Agent’s research analysts
may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or
the Offering that differ from the views of their investment banking division. The Company hereby waives and releases, to the fullest
extent permitted by law, any claims that the Company may have against either Placement Agent with respect to any conflict of interest
that may arise from the fact that the views expressed by its independent research analysts and research departments may be different
from or inconsistent with the views or advice communicated to the Company by such Placement Agent’s investment banking division.
The Company acknowledges that each Placement Agent is a full service securities firm and as such from time to time, subject to
applicable securities laws, rules and regulations, may effect transactions for its own account or the account of its customers
and hold long or short positions in debt or equity securities of the Company; provided, however, that nothing in this Section 18
shall relieve either Placement Agent of any responsibility or liability it may otherwise bear in connection with activities in
violation of applicable securities laws, rules or regulations.


 


19. EFFECTIVENESS. This Agreement shall become effective
upon the execution and delivery hereof by the parties hereto.


 


20. COUNTERPARTS. This Agreement may be signed in any
number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon
the same instrument and such signatures may be delivered by facsimile.


 




    20 


     


    

 


If the foregoing is in accordance with your understanding of
the agreement between the Company and the Placement Agents, kindly indicate your acceptance in the space provided for that purpose
below.


 


	 	Very truly yours,
	 	 
	 	EKSO BIONICS HOLDINGS, INC.
	 	 	 
	 	By: 	/s/ Max Scheder-Bieschin
	 	 	Name: 	Max Scheder-Bieschin
	 	 	 	 
	 	 	Title:	Chief Financial Officer


 


	
        Confirmed as of the date first

        above mentioned, on behalf of

        themselves and the Placement Agents

        named in Schedule C hereto:
	 
	 	 
	LADENBURG THALMANN & CO. INC.	 
	 	 	 
	By:	/s/ David J. Strupp Jr.	 
	 	Name: David J. Strupp Jr.	 
	 	 	 
	 	Title: Managing Director



	 


 





[Signature page to Placement Agency Agreement]


 




    21 


     


    

 


SCHEDULE A 


 


General Use Free Writing Prospectuses



 


None.


 




    22 


     


    

 


SCHEDULE B 


 


Pricing Information 


 


Number of Shares of Preferred Stock to be Issued: 15,000


 


Number of Shares of Common Stock Issuable Upon Exercise of All
Warrants: 14,851,486


 


Number of Shares of Common Stock Issuable Upon Exercise of each
Warrant: 990.1


 


Offering Price: $1,000 per unit


 


Conversion Price: $1.01 per share


 


Warrant Exercise Price: $1.25 per share


 






     23


     


    

 





 





 


SCHEDULE C 


 


	PLACEMENT AGENT	 	NUMBER OF UNITS PLACED	 
	 	 	 	 
	LADENBURG THALMANN & CO. INC.	 	 	12,900	 
	TROUT CAPITAL LLC	 		2,100	 
	 	 	 	 	 
	TOTAL:	 	 	15,000	 



 




     24


     


    

 


SCHEDULE D 


 


Steve Sherman


Nathan Harding


Dan Boren


Marilyn Hamilton


Jack Peurach


Stanley Stern


Amy Wendell


Max Scheder-Bieschin


Thomas Looby


Russ Angold


 




     25


     


    

 


EXHIBIT A 


 


Form of Securities Purchase Agreement



 




     26


     


    

 


EXHIBIT B 


 


Form of Warrant


 




     27


     


    

 


EXHIBIT C 


  


Form of Lock-up Agreement


 


December __, 2015


 


EKSO BIONICS HOLDINGS, INC.


1414 Harbour Way South


Suite 1201


Richmond, CA 94804


 


LADENBURG THALMANN & CO. INC.


As Representative of the Placement Agents


c/o Ladenburg Thalmann & Co. Inc.


570 Lexington Avenue, 11th Floor


New York, NY 10022


 


		Re:	Ekso Bionics Holdings, Inc. (the "Company”) - Restriction on Stock Sales



 


Dear Sirs:


 


This letter is delivered
to you pursuant to the Placement Agency Agreement (the “Placement Agency Agreement”) to be entered into by the Company,
as issuer, and Ladenburg Thalmann & Co. Inc., the representative (the “Representative”) of certain placement agents
(the “Placement Agents”) to be named therein. Upon the terms and subject to the conditions of the Placement Agency
Agreement, the Placement Agents intend to effect a public offering of units (the “Units”) each consisting of one share
of Convertible Preferred Stock, par value $0.001 per share, of the Company and a warrant to purchase shares of the Company’s
Common Stock, par value $0.001 per share, as described in and contemplated by the registration statement of the Company on Form
S-3, File No. 333-205168 (the “Registration Statement”), as filed with the Securities and Exchange Commission on June
23, 2015 (the “Offering”).


 


The undersigned recognizes
that it is in the best financial interests of the undersigned, as an officer or director, or an owner of stock, options, warrants
or other securities of the Company (the “Company Securities”), that the Company complete the proposed Offering.


 


The undersigned further
recognizes that the Company Securities held by the undersigned are, or may be, subject to certain restrictions on transferability,
including those imposed by United States federal securities laws. Notwithstanding these restrictions, the undersigned has agreed
to enter into this letter agreement to further assure the Placement Agents that the Company Securities of the undersigned, now
held or hereafter acquired, will not enter the public market at a time that might impair the placement effort.


 




     28


     


    

 


Therefore, as an inducement
to the Placement Agents to execute the Placement Agent Agreement, the undersigned hereby acknowledges and agrees that the undersigned
will not (i) offer, sell, contract to sell, pledge, grant any option to purchase or otherwise dispose of (collectively, a “Disposition”)
any Company Securities, or any securities convertible into or exercisable or exchangeable for, or any rights to purchase or otherwise
acquire, any Company Securities held by the undersigned or acquired by the undersigned after the date hereof, or that may be deemed
to be beneficially owned by the undersigned (collectively, the “Lock-Up Shares”), pursuant to the Rules and Regulations
promulgated under the Securities Act of 1933, as amended (the “Act”), and the Securities Exchange Act of 1934, as amended,
for a period commencing on the date hereof and ending 90 days after the date of the Company’s Prospectus for the Offering
first filed pursuant to Rule 424(b) under the Act, inclusive (the “Lock-Up Period”), without the prior written consent
of Ladenburg Thalmann & Co. Inc. or (ii) exercise or seek to exercise or effectuate in any manner any rights of any nature
that the undersigned has or may have hereafter to require the Company to register under the Act the undersigned’s sale, transfer
or other disposition of any of the Lock-Up Shares or other securities of the Company held by the undersigned, or to otherwise participate
as a selling securityholder in any manner in any registration effected by the Company under the Act, including under the Registration
Statement, during the Lock-Up Period. The foregoing restrictions are expressly agreed to preclude the undersigned from engaging
in any hedging, collar (whether or not for any consideration) or other transaction that is designed to or reasonably expected to
lead or result in a Disposition of Lock-Up Shares during the Lock-Up Period, even if such Lock-Up Shares would be disposed of by
someone other than such holder. Such prohibited hedging or other transactions would include any short sale or any purchase, sale
or grant of any right (including any put or call option or reversal or cancellation thereof) with respect to any Lock-Up Shares
or with respect to any security (other than a broad-based market basket or index) that includes, relates to or derives any significant
part of its value from Lock-Up Shares.


 


Notwithstanding the
agreement not to make any Disposition during the Lock-Up Period, you have agreed that the foregoing restrictions shall not apply
to:


 


		(1)	the Company Securities being offered in the prospectus included in the Registration Statement;



		(2)	any grant or exercise of options pursuant to the Company’s Amended and Restated 2014 Equity
Incentive Plan;



		(3)	the exercise of currently outstanding warrants to purchase Company Securities;



		(4)	any transaction relating to Company Securities acquired in open market transactions after the completion
of the Offering;
	 	(5)	any
transfer of Company Securities as a bona fide gift;



		(6)	any transfer of Company Securities to a trust for the direct or indirect benefit of the undersigned
or one or more members of the undersigned’s immediate family (which for purposes of this lock-up agreement shall mean any
relationship by blood, marriage or adoption, not more remote than first cousin); or



		(7)	any transfer of Company Securities by will or intestate succession upon the death of the undersigned;



 


			provided that in the case of any transfer or distribution pursuant to clause (5), (6), or
(7), each donee, trustee distributee, or other transferee, as the case may be, shall sign and deliver a lock-up letter substantially
in the form of this letter for the balance of the Lock-up Period.



 









     29


     


    

 


In addition, the
undersigned hereby waives, from the date hereof until the expiration of the Lock-up Period, any and all rights, if any, to request
or demand registration pursuant to the Act, of any shares of Common Stock or securities convertible into or exercisable or exchangeable
for Common Stock that are registered in the name of the undersigned or that are Lock-Up Shares. In order to enable the aforesaid
covenants to be enforced, the undersigned hereby authorizes the Company, and any duly appointed transfer agent for the registration
or transfer of the shares of Common Stock, securities convertible into or exercisable or exchangeable for Common Stock or Lock-Up
Shares, to decline to make any transfer of securities if such transfer would constitute a violation or breach of this letter agreement.


 


It is understood
that, if the Placement Agent Agreement (other than the provisions thereof that survive termination) shall terminate or be terminated
prior to payment for and delivery of the Units, this letter agreement shall automatically terminate.


 


Capitalized terms
used but not defined herein have the respective meanings assigned to such terms in the Placement Agent Agreement.


 


[Rest of page intentionally
left blank.]


 




     30


     


    

 


 


This letter shall
be binding on the undersigned and the respective successors, heirs, personal representatives and assigns of the undersigned.


 


	 	Very truly yours,
	 	 
	 	Signature of Securityholder



 



 




     31